Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Betts

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Haematologica|January 21, 2017
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantationBrian C Betts, Joseph Pidala, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory StudyHemant S Murthy, Kyle Sheets, Ambuj Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial ResultsJoseph Pidala, Kelly Walton, Hany Elmariah, et al.
Nature Medicine|July 22, 2024
Proteomic signatures improve risk prediction for common and rare diseasesJulia Carrasco-Zanini, Maik Pietzner, Jonathan Davitte, et al.
Nature Ecology & Evolution|July 12, 2024
The nature of the last universal common ancestor and its impact on the early Earth systemEdmund R R Moody, Sandra Álvarez-Carretero, Tara A Mahendrarajah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Transplantation and Cellular Therapy|June 13, 2023
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate MofetilNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 20, 2021
Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repairKelly Walton, Kirsti Walker, Megan Riddle, et al.
Blood Cancer Journal|May 19, 2021
High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood groupNajla El Jurdi, Heba Elhusseini, Joan Beckman, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Haematologica|January 21, 2017
IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantationBrian C Betts, Joseph Pidala, Jongphil Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 17, 2017
Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory StudyHemant S Murthy, Kyle Sheets, Ambuj Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial ResultsJoseph Pidala, Kelly Walton, Hany Elmariah, et al.
Nature Medicine|July 22, 2024
Proteomic signatures improve risk prediction for common and rare diseasesJulia Carrasco-Zanini, Maik Pietzner, Jonathan Davitte, et al.
Nature Ecology & Evolution|July 12, 2024
The nature of the last universal common ancestor and its impact on the early Earth systemEdmund R R Moody, Sandra Álvarez-Carretero, Tara A Mahendrarajah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2023
Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict MortalityShernan G Holtan, Constanza Savid-Frontera, Kelly Walton, et al.
Transplantation and Cellular Therapy|June 13, 2023
Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate MofetilNajla El Jurdi, Alex Hoover, Daniel O'Leary, et al.
Blood|July 24, 2024
JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial resultsJoseph Pidala, Shernan G Holtan, Kelly Walton, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 20, 2021
Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repairKelly Walton, Kirsti Walker, Megan Riddle, et al.
Blood Cancer Journal|May 19, 2021
High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood groupNajla El Jurdi, Heba Elhusseini, Joan Beckman, et al.
Pageof 15